KemPharm (KMPH) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of KemPharm (NASDAQ:KMPH) from a hold rating to a buy rating in a report issued on Thursday, August 2nd.

A number of other equities analysts have also commented on KMPH. Zacks Investment Research upgraded KemPharm from a hold rating to a buy rating and set a $7.25 price objective on the stock in a research note on Thursday, April 5th. Canaccord Genuity set a $11.00 price target on KemPharm and gave the company a buy rating in a research note on Thursday, May 24th. Janney Montgomery Scott began coverage on KemPharm in a research note on Wednesday, May 23rd. They issued a buy rating and a $17.00 price target on the stock. Oppenheimer set a $13.00 price target on KemPharm and gave the company a buy rating in a research note on Thursday, May 10th. Finally, Cowen downgraded KemPharm from an outperform rating to a hold rating in a report on Monday, July 9th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $11.21.

KemPharm traded up $0.20, reaching $4.80, on Thursday, according to Marketbeat. The company had a trading volume of 179,760 shares, compared to its average volume of 151,664. KemPharm has a 52 week low of $2.45 and a 52 week high of $8.40. The company has a current ratio of 2.83, a quick ratio of 2.83 and a debt-to-equity ratio of -1.13.

KemPharm (NASDAQ:KMPH) last posted its quarterly earnings data on Friday, August 10th. The specialty pharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.96) by $0.31. equities analysts predict that KemPharm will post -3.45 earnings per share for the current year.

In related news, EVP Daniel L. Cohen acquired 7,900 shares of the stock in a transaction on Tuesday, May 15th. The stock was acquired at an average cost of $6.45 per share, for a total transaction of $50,955.00. Following the completion of the acquisition, the executive vice president now directly owns 35,500 shares of the company’s stock, valued at approximately $228,975. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Delaware Street Capital Master acquired 304,283 shares of the stock in a transaction on Monday, July 30th. The stock was bought at an average price of $4.00 per share, with a total value of $1,217,132.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 312,708 shares of company stock valued at $1,271,290. 25.90% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Change Path LLC purchased a new stake in KemPharm in the first quarter worth about $479,000. Victory Capital Management Inc. lifted its holdings in shares of KemPharm by 10.9% during the first quarter. Victory Capital Management Inc. now owns 179,737 shares of the specialty pharmaceutical company’s stock valued at $1,420,000 after purchasing an additional 17,660 shares during the last quarter. ING Groep NV purchased a new position in shares of KemPharm during the first quarter valued at approximately $1,102,000. JPMorgan Chase & Co. lifted its holdings in shares of KemPharm by 15,976.2% during the first quarter. JPMorgan Chase & Co. now owns 100,637 shares of the specialty pharmaceutical company’s stock valued at $795,000 after purchasing an additional 100,011 shares during the last quarter. Finally, Spark Investment Management LLC purchased a new position in shares of KemPharm during the second quarter valued at approximately $176,000. Institutional investors and hedge funds own 36.41% of the company’s stock.

About KemPharm

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.

Further Reading: Find a Trading Strategy That Works

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply